Andrew Fein Analyst PerformanceMD/Senior Analyst at HC WainwrightAndrew Fein is a stock analyst at HC Wainwright focused in the medical sector, covering 63 publicly traded companies. Over the past year, Andrew Fein has issued 13 stock ratings, including buy and hold recommendations. While full access to Andrew Fein's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Andrew Fein's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings306 Last 11 YearsBuy Recommendations93.98% 281 Buy RatingsCompanies Covered63 Unique Companies Ratings Distribution299RatingsDistribution of strong buy, buy, hold, and sell ratings by Andrew Fein.RatingPercentageCount Strong Buy0.0%0 ratings Buy94.0%281 ratings Hold6.0%18 ratings Sell0.0%0 ratingsOut of 299 total stock ratings issued by Andrew Fein at HC Wainwright, the majority (94.0%) have been Buy recommendations, followed by 6.0% Hold.Best & Worst CallsBest Call0000.0%AMLXMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%BLPHFeb 2020Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ92.1% of companies on NASDAQ58 companiesNYSEAMERICAN3.2% of companies on NYSEAMERICAN2 companiesTSE1.6% of companies on TSE1 companyNYSE1.6% of companies on NYSE1 companyOTCMKTS1.6% of companies on OTCMKTS1 companyAndrew Fein, an analyst at HC Wainwright, currently covers 63 companies listed on NASDAQ, NYSEAMERICAN, TSE, NYSE and OTCMKTS, with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical61 companies96.8%Basic Materials1 company1.6%Aerospace1 company1.6%Andrew Fein of HC Wainwright specializes in stock coverage within the Medical sector, with additional focus on Basic Materials and Aerospace companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE39 companies61.9%MED - DRUGS12 companies19.0%PHARMACEUTICAL PREPARATIONS8 companies12.7%BIOTECHNOLOGY2 companies3.2%MISCELLANEOUS CHEMICAL PRODUCTS1 company1.6%AEROSP/DEF EQ1 company1.6% About Andrew FeinMr. Fein is a Managing Director of Equity Research at H.C. Wainwright. Mr. Fein conducted more than twelve years of biotechnology equity research. Prior to joining H.C. Wainwright, Mr. Fein worked as the Head of the Healthcare Research effort at Chardan Capital Markets. Mr. Fein began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. After that, Mr. Fein worked as a Managing Director/Senior Biotechnology Analyst at Jefferies, Piper Jaffray and Collins Stewart. Mr. Fein has received numerous honorable mentions from the Institutional Investor All-America Research poll. Mr. Fein’s educational background includes a Bachelor of Arts degree from Yale University.Follow on LinkedIn Andrew Fein's Ratings History at HC Wainwright Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsVRTXVertex Pharmaceuticals2/17/2026Set Price Target$491.47$591.00$0.0000.00% ROIKALVKalVista Pharmaceuticals1/9/2026Boost Price Target$15.82$37.00Buy$0.0000.00% ROIDBVTDBV Technologies12/18/2025Set Price Target$20.80$40.00$0.0000.00% ROIAMLXAmylyx Pharmaceuticals11/7/2025Boost Price Target$12.36$20.00Buy$0.0000.00% ROIUTHRUnited Therapeutics10/30/2025Boost Price Target$450.79$525.00Buy$0.0000.00% ROIALECAlector10/22/2025Lower Price Target$1.52$5.00Buy$0.0000.00% ROIAKROAkero Therapeutics10/10/2025Reiterated Rating$54.08$54.00Neutral$0.0000.00% ROIUTHRUnited Therapeutics9/5/2025Boost Price Target$380.47$500.00Buy$0.0000.00% ROIBIIBBiogen8/1/2025Boost Price Target$128.00$194.00Buy$0.0000.00% ROIUTHRUnited Therapeutics7/31/2025Set Price Target$281.95$400.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. FULCFulcrum Therapeutics7/29/2025Upgrade$7.65$12.00Buy$0.0000.00% ROIKALVKalVista Pharmaceuticals7/8/2025Boost Price Target$15.06$27.00Buy$0.0000.00% ROICADLCandel Therapeutics6/30/2025Upgrade$4.90$23.00Buy$0.0000.00% ROIKYMRKymera Therapeutics6/26/2025Reiterated Rating$46.47$60.00Buy$000.0000.00% ROIBIIBBiogen6/26/2025Reiterated Rating$127.31$187.00Buy$000.0000.00% ROIACADACADIA Pharmaceuticals6/26/2025Reiterated Rating$22.50$32.00Buy$00.0000.00% ROIVRTXVertex Pharmaceuticals6/23/2025Reiterated Rating$440.87$550.00Buy$000.0000.00% ROIINSMInsmed6/11/2025Boost Price Target$90.93$120.00Buy$00.0000.00% ROIARVNArvinas6/2/2025Set Price Target$7.51$24.00$0.0000.00% ROISVRASavara5/29/2025Downgrade$2.14$2.00Neutral$0.0000.00% ROIPEPGPepGen5/29/2025Lower Price Target$1.58$8.00Buy$0.0000.00% ROILQDALiquidia5/28/2025Boost Price Target$15.60$35.00Buy$00.0000.00% ROIPRTAProthena5/27/2025Lower Price Target$6.58$14.00Buy$00.0000.00% ROIVIGLVigil Neuroscience5/27/2025Downgrade$7.89$8.00Neutral$0.0000.00% ROIACADACADIA Pharmaceuticals5/19/2025Boost Price Target$22.26$32.00Buy$00.0000.00% ROIANNXAnnexon5/14/2025Lower Price Target$1.75$14.00Buy$0.0000.00% ROISTOKStoke Therapeutics5/14/2025Lower Price Target$8.90$35.00Buy$00.0000.00% ROIINSMInsmed5/12/2025Reiterated Rating$65.08$90.00Buy$000.0000.00% ROILQDALiquidia5/12/2025Reiterated Rating$15.32$29.00Buy$00.0000.00% ROIDYNDyne Therapeutics5/9/2025Lower Price Target$11.32$38.00Buy$00.0000.00% ROIAMLXAmylyx Pharmaceuticals5/9/2025Boost Price Target$4.65$16.00Buy$00.0000.00% ROIPEPGPepGen5/9/2025Lower Price Target$1.58$14.00Buy$0.0000.00% ROIPRTAProthena5/9/2025Lower Price Target$7.43$30.00Buy$00.0000.00% ROIALECAlector5/9/2025Boost Price Target$1.11$10.00Buy$0.0000.00% ROIKROSKeros Therapeutics5/8/2025Lower Price Target$13.68$25.00Buy$00.0000.00% ROIDNLIDenali Therapeutics5/7/2025Lower Price Target$13.55$32.00Buy$00.0000.00% ROIBCRXBioCryst Pharmaceuticals5/6/2025Reiterated Rating$11.03$30.00Buy$0.0000.00% ROIUTHRUnited Therapeutics5/5/2025Reiterated Rating$294.60$425.00Buy$000.0000.00% ROIDBVTDBV Technologies5/5/2025Boost Price Target$8.95$16.00Buy$00.0000.00% ROIBPMCBlueprint Medicines5/2/2025Reiterated Rating$99.25$135.00Buy$0.0000.00% ROICODE RED: AI Meltdown Imminent? (Ad)After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.See the five simple steps to prepare before it's too lateBIIBBiogen5/2/2025Lower Price Target$121.39$187.00Buy$000.0000.00% ROIARVNArvinas5/2/2025Lower Price Target$7.08$24.00Buy$00.0000.00% ROIACIUAC Immune5/1/2025Lower Price Target$1.73$12.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences4/22/2025Lower Price Target$100.68$168.00Buy$000.0000.00% ROIINSMInsmed4/22/2025Reiterated Rating$69.51$90.00Buy$000.0000.00% ROIARVNArvinas4/7/2025Reiterated Rating$6.56$81.00Buy$00.0000.00% ROIIMABI-Mab4/4/2025Lower Price Target$0.73$7.00Buy$0.0000.00% ROIACIUAC Immune4/3/2025Reiterated Rating$1.88$16.00Buy$0.0000.00% ROIKROSKeros Therapeutics4/1/2025Reiterated Rating$10.19$40.00Buy$00.0000.00% ROISVRASavara3/28/2025Reiterated Rating$2.78$6.00Buy$0.0000.00% ROIABOSAcumen Pharmaceuticals3/28/2025Lower Price Target$1.23$11.00Buy$0.0000.00% ROIZNTLZentalis Pharmaceuticals3/27/2025Reiterated Rating$1.76$10.00Buy$0.0000.00% ROIWVEWAVE Life Sciences3/26/2025Reiterated Rating$9.75$22.00Buy$00.0000.00% ROILQDALiquidia3/20/2025Reiterated Rating$14.92$29.00Buy$00.0000.00% ROISTOKStoke Therapeutics3/19/2025Reiterated Rating$8.87$47.00Buy$00.0000.00% ROIZNTLZentalis Pharmaceuticals3/17/2025Reiterated Rating$1.77$10.00Buy$0.0000.00% ROISTROSutro Biopharma3/17/2025Reiterated Rating$8.10$20.00Neutral$00.0000.00% ROIDYNDyne Therapeutics3/17/2025Reiterated Rating$12.23$46.00Buy$00.0000.00% ROIVIGLVigil Neuroscience3/14/2025Lower Price Target$2.11$14.00Buy$0.0000.00% ROIKALVKalVista Pharmaceuticals3/14/2025Reiterated Rating$12.25$20.00Buy$00.0000.00% ROIACIUAC Immune3/14/2025Reiterated Rating$2.30$16.00Buy$0.0000.00% ROIPRQRProQR Therapeutics3/14/2025Boost Price Target$1.74$12.00Buy$0.0000.00% ROIARVNArvinas3/11/2025Reiterated Rating$8.49$81.00Buy$00.0000.00% ROIFHTXFoghorn Therapeutics3/7/2025Reiterated Rating$4.50$13.00Buy$0.0000.00% ROIIBRXImmunityBio3/6/2025Initiated Coverage$3.06$8.00Buy$0.0000.00% ROITARAProtara Therapeutics3/6/2025Reiterated Rating$3.63$23.00Buy$0.0000.00% ROIKMDAKamada3/6/2025Reiterated Rating$7.10$11.00Buy$0.0000.00% ROITCRXTScan Therapeutics3/6/2025Reiterated Rating$1.92$15.00Buy$0.0000.00% ROIAMLXAmylyx Pharmaceuticals3/5/2025Reiterated Rating$3.01$12.00Buy$00.0000.00% ROIWVEWAVE Life Sciences3/5/2025Reiterated Rating$11.23$22.00Buy$00.0000.00% ROIMRUSMerus3/3/2025Reiterated Rating$47.09$85.00Buy$0.0000.00% ROIDYNDyne Therapeutics2/28/2025Lower Price Target$13.17$46.00Buy$00.0000.00% ROIKYMRKymera Therapeutics2/28/2025Boost Price Target$29.98$60.00Buy$00.0000.00% ROIDNLIDenali Therapeutics2/28/2025Boost Price Target$18.60$87.00Buy$00.0000.00% ROICPRXCatalyst Pharmaceuticals2/28/2025Reiterated Rating$21.83$35.00Buy$00.0000.00% ROIKROSKeros Therapeutics2/27/2025Lower Price Target$10.94$40.00Buy$00.0000.00% ROIALECAlector2/27/2025Reiterated Rating$1.72$7.00Buy$0.0000.00% ROIACADACADIA Pharmaceuticals2/27/2025Reiterated Rating$18.96$27.00Buy$00.0000.00% ROIUTHRUnited Therapeutics2/27/2025Reiterated Rating$318.89$425.00Buy$000.0000.00% ROIBCRXBioCryst Pharmaceuticals2/25/2025Reiterated Rating$8.29$30.00Buy$0.0000.00% ROIPEPGPepGen2/24/2025Reiterated Rating$2.81$16.00Buy$0.0000.00% ROINBIXNeurocrine Biosciences2/21/2025Reiterated Rating$116.11$185.00Buy$000.0000.00% ROIINSMInsmed2/21/2025Reiterated Rating$83.61$90.00Buy$000.0000.00% ROIPRTAProthena2/21/2025Reiterated Rating$15.25$48.00Buy$0.0000.00% ROICRBPCorbus Pharmaceuticals2/18/2025Reiterated Rating$8.51$75.00Buy$0.0000.00% ROISTOKStoke Therapeutics2/18/2025Boost Price Target$9.74$47.00Buy$00.0000.00% ROIBPMCBlueprint Medicines2/14/2025Reiterated Rating$95.19$135.00Buy$0.0000.00% ROIBIIBBiogen2/13/2025Lower Price Target$133.43$241.00Buy$000.0000.00% ROIVRTXVertex Pharmaceuticals2/11/2025Reiterated Rating$469.97$550.00Buy$000.0000.00% ROICRBPCorbus Pharmaceuticals2/10/2025Reiterated Rating$10.15$75.00Buy$0.0000.00% ROITrump's gold order: the announcement they won't put on the front page (Ad)On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.Request the free guide in 30 seconds and get positioned nowNBIXNeurocrine Biosciences2/7/2025Lower Price Target$150.51$185.00Buy$000.0000.00% ROIVRTXVertex Pharmaceuticals1/31/2025Boost Price Target$438.40$550.00Buy$000.0000.00% ROIPEPGPepGen1/30/2025Lower Price Target$1.84$16.00Buy$0.0000.00% ROIZNTLZentalis Pharmaceuticals1/29/2025Lower Price Target$1.98$10.00Buy$0.0000.00% ROIVIGLVigil Neuroscience1/23/2025Reiterated Rating$2.51$17.00Buy$0.0000.00% ROIKMDAKamada1/10/2025Reiterated Rating$7.32$11.00Buy$0.0000.00% ROICPRXCatalyst Pharmaceuticals1/10/2025Boost Price Target$22.80$35.00Buy$00.0000.00% ROICGONCG Oncology1/10/2025Reiterated Rating$30.24$75.00Buy$00.0000.00% ROIDYNDyne Therapeutics1/10/2025Reiterated Rating$15.68$55.00Buy$00.0000.00% ROIAMLXAmylyx Pharmaceuticals10/18/2024Reiterated Rating$3.92$8.00Buy$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerDeutsche Bank AktiengesellschaftStifel Nicolaus Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.